Abeona Therapeutics Inc vs Rent the Runway Inc — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while Rent the Runway Inc trades at $3.64 (market cap $122.65M). The key difference: Abeona Therapeutics Inc is far larger — about 3.4× Rent the Runway Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | RENT | |
|---|---|---|
Market Cap | $421.19M | $122.65M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $9.39 |
52-Week Low | $4.17 | $3.01 |
Enterprise Value | $276.10M | $282.75M |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Rent the Runway (RENT) trades at $3.70, up 1.65% with a bullish technical signal. The company shows improving fundamentals with Q1 2026 revenue growth of 29.2% to $89.9M and narrowing losses. Despite negative equity of -$182.5M, valuation metrics appear attractive with P/E of 0.48 and P/S of 0.2. Recent leadership transition with Teri Bariquit as interim CEO brings fresh perspective to the subscription fashion platform.
The outlook remains cautiously optimistic with analyst consensus leaning buy (42%) though profitability challenges persist. Key opportunities include subscriber growth and margin improvement, while risks involve high debt load and competitive pressure. The stock offers speculative upside if the company can achieve projected 2026 profitability of $30M net income.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →